Advertisement

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

Anas Younes, Yasuhiro Oki, Peter McLaughlin, Amanda R. Copeland, Andre Goy, Barbara Pro, Lei Feng, Ying Yuan, Hubert H. Chuang, Homer A. Macapinlac, Fredrick Hagemeister, Jorge Romaguera, Felipe Samaniego, Michelle A. Fanale, Bouthaina Shbib Dabaja, Maria A. Rodriguez, Nam Dang, Larry W. Kwak, Sattva S. Neelapu and Luis E. Fayad

Article Information

Citation 
vol. 119 no. 18 4123-4128
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted January 24, 2012
  • Accepted January 31, 2012
  • Published online May 3, 2012.

Article Versions


Contributors 
  • Anas Younes, Departments of 1Lymphoma and Myeloma,
  • Yasuhiro Oki, Departments of 1Lymphoma and Myeloma,
  • Peter McLaughlin, Departments of 1Lymphoma and Myeloma,
  • Amanda R. Copeland, Departments of 1Lymphoma and Myeloma,
  • Andre Goy, Departments of 1Lymphoma and Myeloma,
  • Barbara Pro, Departments of 1Lymphoma and Myeloma,
  • Lei Feng, 2Biostatistics,
  • Ying Yuan, 2Biostatistics,
  • Hubert H. Chuang, 3Nuclear Medicine, and
  • Homer A. Macapinlac, 3Nuclear Medicine, and
  • Fredrick Hagemeister, Departments of 1Lymphoma and Myeloma,
  • Jorge Romaguera, Departments of 1Lymphoma and Myeloma,
  • Felipe Samaniego, Departments of 1Lymphoma and Myeloma,
  • Michelle A. Fanale, Departments of 1Lymphoma and Myeloma,
  • Bouthaina Shbib Dabaja, 4Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Maria A. Rodriguez, Departments of 1Lymphoma and Myeloma,
  • Nam Dang, Departments of 1Lymphoma and Myeloma,
  • Larry W. Kwak, Departments of 1Lymphoma and Myeloma,
  • Sattva S. Neelapu, Departments of 1Lymphoma and Myeloma,
  • Luis E. Fayad, Departments of 1Lymphoma and Myeloma,

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output